Smith & Nephew plc stock (GB0009223206): orthopedic specialist lifts guidance after strong 2024 results

Smith & Nephew plc recently reported solid 2024 results and raised its 2025 guidance, highlighting momentum in orthopedics and sports medicine while continuing a multi-year efficiency program.

Smith & Nephew plc has drawn renewed investor attention after reporting its results for the financial year 2024 and lifting guidance for 2025, reflecting improving profitability and steady demand for orthopedic implants and sports medicine products, according to a results release published on 02/20/2025 on the company’s website and coverage from Reuters as of 02/20/2025.

As of: 18.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Smith & Nephew
• Sector/industry: Medical devices / orthopedics
• Headquarters/country: London, United Kingdom
• Core markets: Orthopedic reconstruction, sports medicine, advanced wound management
• Key revenue drivers: Hip and knee implants, trauma products, sports medicine technologies, wound care solutions
• Home exchange/listing venue: London Stock Exchange (ticker: SN)
• Trading currency: GBP

Smith & Nephew plc: core business model

Smith & Nephew focuses on medical devices for orthopedics, sports medicine and wound care, positioning itself as a specialist supplier to hospitals and clinics globally. The company’s portfolio spans hip and knee reconstruction, trauma fixation systems, arthroscopy equipment, and products to treat acute and chronic wounds. Management emphasizes innovation and surgeon relationships as central to its competitive positioning.

Within orthopedics, Smith & Nephew offers joint replacement systems designed to restore mobility after degenerative disease or trauma. In sports medicine, the company sells devices for minimally invasive procedures on ligaments, tendons and cartilage, targeting a broad population of active patients. Advanced wound management covers dressings and therapies aimed at accelerating healing and reducing complications, particularly in diabetic and elderly populations.

The business model is built on recurring demand from surgical procedures, hospital purchasing contracts and long-term product lifecycles. While new technology launches can shift market share, established implants and instruments tend to remain in use for years due to surgeon familiarity and regulatory requirements, supporting relatively stable revenue streams once products are adopted.

Main revenue and product drivers for Smith & Nephew plc

For the year 2024, Smith & Nephew reported revenue growth driven by solid performance in orthopedics and sports medicine, with advanced wound management contributing more modestly, according to the company’s full-year results statement published on 02/20/2025 on its investor relations site and summarized by Reuters as of 02/20/2025. Management highlighted procedure volume recovery and successful launches of new implant systems as key contributors.

Orthopedics remains the largest revenue pillar, reflecting demand for hip and knee replacements and trauma products. Industry-wide, aging populations in North America and Europe and growing access to care in emerging markets support long-term procedure growth. For Smith & Nephew, this structural trend underpins investment in next-generation implant designs and robotics-assisted surgery platforms, which can deepen integration with hospital workflows and potentially support pricing.

Sports medicine and ear, nose and throat products form another important driver, benefiting from expansion in minimally invasive procedures. The segment includes arthroscopic instruments, joint repair implants and biologics used in soft tissue healing. Sports medicine revenues tend to correlate with activity levels and sports participation, but also with broader adoption of arthroscopic techniques for joint repair in older patients.

Advanced wound management, while smaller than orthopedics, provides diversification and exposure to chronic care settings. Smith & Nephew offers foam dressings, negative pressure wound therapy systems and advanced materials designed to support healing in complex wounds. Demand in this area is influenced by hospital protocols, reimbursement structures and the prevalence of diabetes and vascular disease, particularly in the United States and Europe.

Industry trends and competitive position

The global orthopedic and wound care markets are characterized by high regulatory requirements, long product development cycles and significant R&D investment. Smith & Nephew competes with larger diversified peers and specialized device makers, particularly in joint reconstruction and sports medicine. Market share is influenced by clinical data, surgeon training, service quality and procurement negotiations with hospital systems.

Long-term drivers such as demographic aging, higher rates of obesity and increased expectations for mobility in older age groups support procedure growth. At the same time, healthcare systems in the United States and Europe continue to focus on cost containment, creating pressure on pricing and favoring suppliers that can offer efficiency gains. Smith & Nephew’s multi-year productivity and margin improvement program, highlighted again in the 2024 results announcement on 02/20/2025, is part of its response to these structural pressures.

Technological shifts, including surgical robotics, navigation, and data-driven operating room tools, are reshaping competitive dynamics. Larger players have invested heavily in robotics ecosystems. Smith & Nephew has also developed its own robotic-assisted platform for knee surgery, aiming to differentiate on ease of use and workflow integration. Adoption levels, surgeon feedback and long-term outcomes will influence how strongly such systems contribute to market positioning.

Why Smith & Nephew plc matters for US investors

Although Smith & Nephew is headquartered in the United Kingdom and listed on the London Stock Exchange, the company generates a significant portion of its revenue in the United States, one of the largest markets for orthopedic procedures and wound care. US investors are exposed to familiar healthcare themes such as demographic aging, procedure volume growth and innovation in minimally invasive surgery through the stock.

The company’s products are used across US hospitals and outpatient surgery centers, placing it within the broader US medical device supply chain. Changes in US reimbursement rules, hospital consolidation or shifts toward value-based care can therefore affect revenue and margins. Investors focused on the US healthcare ecosystem may view Smith & Nephew alongside domestic medical device names when considering sector diversification.

US dollar exposure is another consideration, as revenue generated in the United States must be translated into the company’s reporting currency. Exchange rate movements between the US dollar and British pound can affect reported results and, in turn, investor perception. In its commentary around the 2024 results on 02/20/2025, management again referred to currency as one of several external factors influencing reported performance alongside operational improvements.

Conclusion

Smith & Nephew plc combines exposure to structural healthcare themes with the specific dynamics of orthopedic and wound care markets. The company’s 2024 results and 2025 guidance increase, released on 02/20/2025, underline management’s focus on margin recovery and operational efficiency while sustaining investment in innovation. For investors following global medical device names, the stock offers a way to participate in surgical procedure growth and hospital technology trends, balanced by typical sector risks such as regulatory scrutiny, pricing pressure and competition from larger peers.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.